Overview
- About 5,000 of the job reductions will be in Denmark, part of a global restructuring across the company.
- The company targets roughly 8 billion Danish kroner in annual savings by the end of 2026 from the workforce reduction.
- Operating-margin guidance for 2025 was cut to 4%–10%, down from the previously signaled 10%–16%.
- CEO Mike Doustdar framed the move as a shift toward stricter performance, prioritized spending in core therapies, and expanded production capacity.
- Novo pointed to pressure from Eli Lilly and continued U.S. pharmacy ‘personalized’ preparations after a temporary compounding authorization ended on May 22.